British firm presents treatment trial slashing COVID-19 death risk | AFP

In an online press conference, researchers from British biotech firm Synairgen detail an aerosol-based drug treatment using the protein interferon beta that could drastically reduce the number of new coronavirus patients dying from the disease or requiring intensive care, according to preliminary results.

Subscribe to AFP and activate your notifications to get the latest news đź””